Media Contact:
Christina Panta
KCSA Strategic Communications
212.896.1208
cpanta@kcsa.com

The Cannabis ETF (THCX) Announces Strategic Advisor Additions

Jon and Pete Najarian to Welcome Cannabis Investment Veteran and Biotech Entrepreneur

NEW YORK (August 8, 2019) –The Cannabis ETF (THCX), the first passively managed pure-play ETF solution for investing in cannabis, today announced an expansion of its strategic advisor team. Joining Jon and Pete Najarian, CNBC contributors, co-founders of Investitute and optionMONSTER, will be Stable Road Capital CIO, Brian Kabot, and healthcare and biotechnology entrepreneur, Neal Patel, Ph.D. We believe their collaborative industry knowledge and partnership expand THCX’s presence in the cannabis investment marketplace while their leadership experience and insights add to the fund’s already deep bench of cannabis experts.

“Over the years I’ve been drawn to investing in disruptive industries and I believe that cannabis is in the very early innings of what could prove to be a generational investment opportunity. THCX offers investors a solution for what they’ve been asking: a diversified, liquid and cost-efficient vehicle which best navigates the ever-changing landscape of the global green rush,” said Jon Najarian, strategic advisor to The Cannabis ETF.

Brian Kabot has more than 19 years of principal investing experience on Wall Street. In July 2017, he accepted the position of Chief Investment Officer at Stable Road Capital, where he focuses on acquiring and investing in high quality operating businesses, assets and funds – specifically working in the cannabis investing space. Prior to that, he was a Founding Partner of Riverloft Capital, a cross cap structure, event-driven hedge fund.

Neal Patel, Ph.D., is a healthcare and biotechnology entrepreneur in the pharmaceutical and medical cannabis industries. Dr. Patel helped develop clinical protocols for pharma blue-chips such as Sanofi, Regeneron, Pfizer, Bayer AG, Novartis, and GlaxoSmithKline and has been instrumental in the FDA approval of 5 new molecules through his collaborations. Currently, Dr. Patel serves as Founder and Principal of Tendaji Ventures, an early stage incubator that initiates and maintains research partnerships between biotech and pharmaceutical companies looking to enter the medical cannabis arena. Patel is also a strategic investor for various healthcare companies that have recently devoted exploratory attention to cannabis-based science including PathogenDX and CannBioRx.

“The Najarian brothers have been renowned investors over the past three decades, and with the addition of both Dr. Patel and Brian Kabot, we have deepened our bench of cannabis experts. We are excited to add not only such a high level of institutional investment acumen but a brilliant scientific and medical perspective as well,” said Matt Markiewicz, Managing Director, Innovation Shares. “In addition to providing ongoing counsel for Innovation Shares’ strategic direction, our esteemed team of strategic advisors will help us leverage fresh perspectives in order to expand THCX’s presence in investors’ portfolios.”

Currently listed on the NYSE Arca, THCX tracks the Innovation Labs Cannabis Index, a rules-based portfolio which rebalances on a monthly basis. The index consists of 35 stocks that are expected to benefit from the rise in value of the global cannabis market which is estimated to reach $630 billion by 20401. THCX’s 70 bps management fee makes it the lowest-cost passively managed US-listed cannabis ETF.2

None of the strategic advisors to The Cannabis ETF have an affiliation to the Fund’s Advisor, OBP Capital LLC.

Please visit THCXetf.com for more information.

# # #

About Innovation Shares LLC
Innovation Shares builds cutting-edge portfolios around growing and disruptive thematic investment trends. The true innovation behind its strategy is the AI powered natural language processing algorithm used to help identify sentiment around themes and relevant stocks.